Q-omics provides the consensus-scored POMGNT2 profile across patient tissues and cancer cell-line models. POMGNT2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, POMGNT2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, POMGNT2 RNA expression shows 18,772 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where POMGNT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POMGNT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POMGNT2 survival associations across molecular data types. POMGNT2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POMGNT2 RNA expression–survival associations across cancer types. High POMGNT2 expression shows unfavorable associations in LIHC, but favorable associations in UVM, BRCA, KIRC, READ and LGG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for POMGNT2 RNA expression.
This table summarizes POMGNT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POMGNT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POMGNT2 shows lower tumor expression in KIRC, KICH, THCA and LUAD and higher tumor expression in COAD and LIHC. The KIRC box plot shows higher POMGNT2 RNA expression in normal versus tumor tissue (log2 FC = −1.046, t-test p < 0.001).
This table shows molecular features associated with POMGNT2 in patient tissues and cancer cell lines. In patient samples, POMGNT2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, POMGNT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
